Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

HAVN Life Sciences Inc. (HAVN.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.16000.0000 (0.00%)
At close: 02:44PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1600
Open0.1650
Bid0.1500 x N/A
Ask0.1650 x N/A
Day's Range0.1500 - 0.1650
52 Week Range0.1450 - 1.0700
Volume76,661
Avg. Volume155,704
Market Cap20.334M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    HAVN Life Announces Gary Leong's Appointment to Board of Directors

    HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind, is pleased to announce the appointment of Mr. Gary Leong to its Board of Directors. Concurrently, Mr. Leong has stepped down as HAVN Life's Chief Science Officer, shifting his focus to an advisory role within the organization.

  • CNW Group

    HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.

    Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company developing natural health products and innovative therapies to support central nervous system health and enhance the capabilities of the mind, is pleased to announce it has entered into a definitive agreement (the "Definitive Agreement") to acquire (the "Acquisition") all of the outstanding securities of Spore Life Sciences Inc. ("Spore"), on the terms and conditions set forth in t

  • CNW Group

    HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes

    Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential active pharmaceutical ingredients (APIs) to support brain health, is pleased to announce it has successfully exported naturally derived psilocybin from its facility in Jamaica into the U.S.

Advertisement
Advertisement